Translational Medical Oncology and Individualized Cancer Therapy

Jacquin, JP; Jones, S; Magne, N; Chapelle, C; Ellis, P; Janni, W; Mavroudis, D; Martin, M; Laporte, S.

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

BREAST CANCER RESEARCH AND TREATMENT. 2012; 134(3): 903-913 No. of citations: 32 [doi:10.1007/s10549-011-1933-0]

Virizuela, JA; Escobar, Y; Cassinello, J; Borrega, P.

Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice

Clinical & Translational Oncology. 2012; 14(7): 499-504 No. of citations: 30 [doi:10.1007/s12094-012-0831-1]

Chen, AC; Migliaccio, I; Rimawi, M; Lopez-Tarruella, S; Creighton, CJ; Massarweh, S; Huang, C; Wang, YC; Batra, SK; Gutierrez, MC; Osborne, CK; Schiff, R.

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

BREAST CANCER RESEARCH AND TREATMENT. 2012; 134(2): 583-593 No. of citations: 33 [doi:10.1007/s10549-012-2082-9]

Romero, A; Martin, M; Oliva, B; de la Torre, J; Furio, V; de la Hoya, M; Garcia-Saenz, JA; Moreno, A; Roman, JM; Diaz-Rubio, E; Caldes, T.

Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients

ANNALS OF ONCOLOGY. 2012; 23(7): 1750-1756 No. of citations: 38 [doi:10.1093/annonc/mdr483]

Hurvitz, SA; Betting, DJ; Stem, HM; Quinaux, E; Stinson, J; Seshagiri, S; Zhao, Y; Buyse, M; Mackey, J; Driga, A; Damaraju, S; Sliwkowski, MX; Robert, NJ; Valero, V; Crown, J; Falkson, C; Brufsky, A; Pienkowski, T; Eiermann, W; Martin, M; Bee, V; Marathe, O; Slamon, DJ; Timmerman, JM.

Analysis of Fc gamma Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

CLINICAL CANCER RESEARCH. 2012; 18(12): 3478-3486 No. of citations: 106 [doi:10.1158/1078-0432.CCR-11-2294]

Lopez-Tarruella, S; Jerez, Y; Marquez-Rodas, I; Martin, M.

Neratinib (HKI-272) in the treatment of breast cancer

Future Oncology. 2012; 8(6): 671-681 No. of citations: 32 [doi:10.2217/FON.12.66]

Guisado-Vasco, P; Arranz-Saez, R; Canales, M; Canovas, A; Garcia-Larana, J; Garcia-Sanz, R; Lopez, A; Lopez, JL; Llanos, M; Moraleda, JM; Rodriguez, J; Rayon, C; Sabin, P; Salar, A; Marin-Niebla, A; Morente, M; Sanchez-Godoy, P; Tomas, JF; Muriel, A; Abraira, V; Piris, MA; Garcia, JF; Montalban, C.

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

LEUKEMIA & LYMPHOMA. 2012; 53(5): 812-819 No. of citations: 15 [doi:10.3109/10428194.2011.635861]

Martin, M; Makhson, A; Gligorov, J; Lichinitser, M; Lluch, A; Semiglazov, V; Scotto, N; Mitchell, L; Tjulandin, S.

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

ONCOLOGIST. 2012; 17(4): 469-475 No. of citations: 39 [doi:10.1634/theoncologist.2011-0344]

Gutierrez, LC; Khosravi-Shahi, P; Alvarez, YE.

Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy

ORAL ONCOLOGY. 2012; 48(4): 293-297 No. of citations: 19 [doi:10.1016/j.oraloncology.2011.10.019]

Romero, A; Caldes, T; Diaz-Rubio, E; Martin, M.

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Clinical & Translational Oncology. 2012; 14(3): 163-168 No. of citations: 26 [doi:10.1007/s12094-012-0779-1]

Albanell, J; Gonzalez, A; Ruiz-Borrego, M; Alba, E; Garcia-Saenz, JA; Corominas, JM; Burgues, O; Furio, V; Rojo, A; Palacios, J; Bermejo, B; Martinez-Garcia, M; Limon, ML; Munoz, AS; Martin, M; Tusquets, I; Rojo, F; Colomer, R; Faull, I; Lluch, A.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer

ANNALS OF ONCOLOGY. 2012; 23(3): 625-631 No. of citations: 104 [doi:10.1093/annonc/mdr278]

Rosell, R; Carcereny, E; Gervais, R; Vergnenegre, A; Massuti, B; Felip, E; Palmero, R; Garcia-Gomez, R; Pallares, C; Sanchez, JM; Porta, R; Cobo, M; Garrido, P; Longo, F; Moran, T; Insa, A; De Marinis, F; Corre, R; Bover, I; Illiano, A; Dansin, E; de Castro, J; Milella, M; Reguart, N; Altavilla, G; Jimenez, U; Provencio, M; Moreno, MA; Terrasa, J; Munoz-Langa, J; Valdivia, J; Isla, D; Domine, M; Molinier, O; Mazieres, J; Baize, N; Garcia-Campelo, R; Robinet, G; Rodriguez-Abreu, D; Lopez-Vivanco, G; Gebbia, V; Ferrera-Delgado, L; Bombaron, P; Bernabe, R; Bearz, A; Artal, A; Cortesi, E; Rolfo, C; Sanchez-Ronco, M; Drozdowskyj, A; Queralt, C; de Aguirre, I; Ramirez, JL; Sanchez, JJ; Molina, MA; Taron, M; Paz-Ares, L.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

LANCET ONCOLOGY. 2012; 13(3): 239-246 No. of citations: 5272 [doi:10.1016/S1470-2045(11)70393-X]

Miles, D; Zielinski, C; Martin, M; Vrdoljak, E; Robert, N.

Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review

EUROPEAN JOURNAL OF CANCER. 2012; 48(4): 482-491 No. of citations: 16 [doi:10.1016/j.ejca.2011.12.007]

Eiermann, W; Bergh, J; Cardoso, F; Conte, P; Crown, J; Curtin, NJ; Gligorov, J; Gusterson, B; Joensuu, H; Linderholm, BK; Martin, M; Penault-Llorca, F; Pestalozzi, BC; Razis, E; Sotiriou, C; Tjulandin, S; Viale, G.

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

BREAST. 2012; 21(1): 20-26 No. of citations: 28 [doi:10.1016/j.breast.2011.09.006]

Arija, JAA; Beca, RG; Lopez, CL; Dominguez, PS; Lovelle, AS; Gilarranz, YJ.

Treatment of the patient with castration-resistant biochemical progression of prostate cancer

ARCHIVOS ESPANOLES DE UROLOGIA. 2012; 65(1): 185-192 No. of citations: 1

Sorensen, SV; Goh, JW; Pan, F; Chen, C; Yardley, D; Martin, M; Knopf, K; Benedict, A; Giorgetti, C; Iyer, S.

INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2012; 28(1): 12-21 No. of citations: 70 [doi:10.1017/S026646231100064X]

Marquez-Rodas, I; Lopez-Trabada, D; Blanco, ABR; Cabello, SC; Gomez, MIP; Clemente, MO; Calvo, FA; Martin, M.

Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study

ONCOLOGY. 2012; 82(1): 30-34 No. of citations: 6 [doi:10.1159/000335960]

Llombart-Cussac, A; Ruiz, A; Anton, A; Barnadas, A; Antolin, S; Ales-Martinez, JE; Alvarez, I; Andres, R; Saenz, JAG; Lao, J; Carrasco, E; Camara, C; Casas, I; Martin, M.

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial

CANCER. 2012; 118(1): 241-247 No. of citations: 27 [doi:10.1002/cncr.26299]